Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 ...

Novavax expects 2026 adjusted revenue between $185 million and $205 million, excluding royalties and sales from its licensing ...

Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald initiated coverage of Novavax, Inc. (NASDAQ:NVAX) with an Overweight rating and a ...

Objectives The Omicron variant of SARS-CoV-2 has emerged as the predominant strain of COVID-19 since 2022. Its association with prior vaccines remained under investigation. Design Retrospective cohort ...

In an effort to save and shift away from manufacturing, Novavax is decreasing its footprint in Montgomery County. Plans are already underway for the vaccine maker to turn over the lease for its ...

Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million Novavax headquarters to remain in ...

Novavax (NASDAQ:NVAX) on Wednesday announced an agreement to assign its Gaithersburg, Maryland, facility and certain assets to AstraZeneca (NASDAQ:AZN) as part of two separate deals worth nearly $60M.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The property was “not needed ...

With plans to pay up to $2.1 billion to acquire its Dublin, Ireland, neighbor Avadel Pharmaceuticals, Alkermes is hoping to gain an immediate growth driver in narcolepsy drug Lumryz. But perhaps more ...